People: Accelerate Diagnostics Inc (AXDX.O)
AXDX.O on Consolidated Issue listed on NASDAQ Capital Market
8.67USD
24 May 2013
8.67USD
24 May 2013
Price Change (% chg)
$0.07 (+0.81%)
$0.07 (+0.81%)
Prev Close
$8.60
$8.60
Open
$8.57
$8.57
Day's High
$8.70
$8.70
Day's Low
$8.49
$8.49
Volume
43,420
43,420
Avg. Vol
70,337
70,337
52-wk High
$8.99
$8.99
52-wk Low
$2.46
$2.46
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
John Patience |
65 | 2012 | Independent Chairman of the Board |
Lawrence Mehren |
45 | 2012 | President, Chief Executive Officer, Director |
Steve Reichling |
34 | 2012 | Chief Financial Officer |
Thomas Geimer |
65 | 2012 | Director |
Frank ten Brink |
56 | 2013 | Director |
Jack Schuler |
72 | 2012 | Independent Director |
Matthew Strobeck |
39 | 2012 | Independent Director |
Biographies
| Name | Description |
|---|---|
John Patience |
Mr. John Patience is Independent Chairman of the Board of Accelerate Diagnostics Inc. He has served as a Director of the Company since June 26, 2012. Mr. Patience is also a founding partner of Crabtree Partners, a private equity investment firm. Mr. Patience served as a director of Ventana Medical Systems, Inc. from 1989 and as Vice Chairman from 1999 until Ventana’s acquisition by Roche in 2008. Mr. Patience has been a director of Stericycle, Inc. (NASDAQ: SRCL) since 1989. Mr. Patience was previously a partner of a venture capital investment firm that provided both Ventana and Stericycle with early stage funding. Mr. Patience was also previously a partner in the consulting firm of McKinsey & Co., Inc., specializing in health care. Mr. Patience holds a B.A. in Liberal Arts and an L.L.B. from the University of Sydney, Australia, and an M.B.A. from the University of Pennsylvania’s Wharton School of Business. |
Lawrence Mehren |
Mr. Lawrence Mehren is President, Chief Executive Officer, Director of Accelerate Diagnostics Inc. He has served as the Chief Executive Officer and a Director of the Company since June 26, 2012. Mr. Mehren served as Senior Vice President and Chief Financial Officer of Ventana Medical Systems from 2007 until 2008 and as Head of Global Business from 2008 until 2011. Previously, he was Managing Director, Partner and head of P&M Corporate Finance’s (an investment banking firm based in Detroit, Michigan) life sciences practice. Prior to his tenure at P&M, Mr. Mehren worked in management positions with Gale Group, a division of The Thomson Corporation, as well as Merrill Lynch. Mr. Mehren holds a B.A. in Political Science from the University of Arizona and an M.B.A. from Northwestern University’s Kellogg Graduate School of Management. |
Steve Reichling |
Mr. Steve Reichling is Chief Financial Officer of Accelerate Diagnostics Inc., since August 10, 2012. Prior to joining the Company, Mr. Reichling served as general manager of Spring Bioscience Corp., a R&D and research products subsidiary of Roche Tissue Diagnostics. From January 2003 to December 2009, Mr. Reichling held various finance, accounting and operations leadership roles at Roche Tissue Diagnostics and Ventana Medical Systems, Inc., including director of finance and operations, manager of business development finance, and head of Internal Audit and Sarbanes Oxley Compliance. From October 2002 to January 2003, Mr. Reichling was an auditor at Ernst & Young LLP. Mr. Reichling received his B.A. in accounting and entrepreneurship from the University of Arizona and is a Certified Public Accountant. |
Thomas Geimer |
Mr. Thomas V. Geimer is Director of Accelerate Diagnostics Inc. Mr. Geimer was the Chairman of the Board of Accelr8 from 1987 to 2012. He has served as a Director of the Company since 1987 and as the Chief Executive Officer, Chief Financial Officer and Secretary of the Company from 1987 until June 2012. Before assuming full-time responsibilities at the Company, Mr. Geimer founded and operated an investment banking firm. |
Frank ten Brink |
Mr. Frank J. M. ten Brink has been appointed as Director of Accelerate Diagnostics, Inc., effective March 6, 2013. Mr. ten Brink has served as Executive Vice President, Chief Financial Officer and Chief Administrative Officer of Stericycle, Inc. (NASDAQ: SRCL) since June 1997. He has over 16 years of finance experience in high growth environments, mergers and acquisitions. Prior to joining Stericycle, Mr. ten Brink was Senior Vice President and Chief Financial Officer with Telular Corporation. Between 1991 and 1995, he was Vice President and Chief Financial Officer of Hexacomb Corporation. Mr. ten Brink studied International Business at the Netherlands School of Business and received an M.B.A. degree in Finance from the University of Oregon. |
Jack Schuler |
Mr. Jack W. Schuler is Independent Director of Accelerate Diagnostics Inc., since June 26, 2012. Mr. Schuler is a founding partner of Crabtree Partners, a private equity investment firm. Mr. Schuler served as a director of Ventana Medical Systems, Inc. from 1991 and as Chairman of the Board from 1995 until Ventana’s acquisition by Roche in 2008. Mr. Schuler has been a director of Stericycle, Inc. (NASDAQ: SRCL) since March 1990, formerly serving as Chairman of the Board, and continues to serve as Lead Director for Stericyle. Prior to joining Stericycle, Inc., Mr. Schuler held various executive positions at Abbott Laboratories from December 1972 through August 1989, most recently serving as President and Chief Operating Officer. He is currently a director of Quidel Corporation (NASDAQ: QDEL) and Medtronic, Inc. (NYSE: MDT). Mr. Schuler holds a B.S. in Mechanical Engineering from Tufts University and an M.B.A. from Stanford University. |
Matthew Strobeck |
Dr. Matthew W. Strobeck, Ph.D., is Independent Director of Accelerate Diagnostics Inc., since July 7, 2012. Dr. Strobeck currently serves as a director of Metabolix, Inc. (NASDAQ: MBLX), an innovation-driven bioscience company focused on delivering sustainable solutions to the plastics, chemicals and energy industries. He was a Partner and Member of the Management Committee and Advisory Board of Westfield Capital Management from 2008 until 2011, having served as a member of the investment team, specializing in healthcare and life sciences, from May 2003 to June 2008. Dr. Strobeck was a fellow in the Department of Biology at MIT from December 2001 to June 2002. Dr. Strobeck received his B.S. from St. Lawrence University, a Ph.D. from the University of Cincinnati, a S.M. from Harvard University/MIT Health Sciences Technology Program, and a S.M. from the MIT Sloan School of Management. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
John Patience |
-- |
Lawrence Mehren |
1,152,050 |
Steve Reichling |
-- |
Thomas Geimer |
977,652 |
Frank ten Brink |
-- |
Jack Schuler |
-- |
Matthew Strobeck |
-- |
As Of 30 Jul 2012
Options Compensation
| Name | Options | Value |
|---|---|---|
John Patience |
0 | 0 |
Lawrence Mehren |
0 | 0 |
Steve Reichling |
0 | 0 |
Thomas Geimer |
300,000 | 227,000 |
Frank ten Brink |
0 | 0 |
Jack Schuler |
0 | 0 |
Matthew Strobeck |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
PATIENCE JOHN |
13,428,840 | $0.00 |
PATIENCE JOHN |
6,428,840 | $2.00 |
MEHREN LAWRENCE |
6,428,840 | $2.00 |
SCHULER JACK W |
8,043,004 | $0.00 |
SCHULER JACK W |
6,428,840 | $2.00 |
PATIENCE JOHN |
7,000,000 | $1.03 |
MEHREN LAWRENCE |
7,000,000 | $1.03 |
STROBECK MATTHEW |
1,911,263 | $0.00 |
SCHULER JACK W |
13,428,840 | $0.00 |
SCHULER JACK W |
7,000,000 | $1.03 |
MEHREN LAWRENCE |
13,428,840 | $0.00 |
PATIENCE JOHN |
14,000,000 | $0.00 |
ABEJA VENTURES L L C |
7,000,000 | $1.03 |
ABEJA VENTURES L L C |
13,428,840 | $0.00 |
ABEJA VENTURES L L C |
6,428,840 | $2.00 |
MEHREN LAWRENCE |
14,000,000 | $0.00 |
SCHULER JACK W |
14,000,000 | $0.00 |
MEHREN LAWRENCE |
1,576,792 | $0.00 |
PATIENCE JOHN |
5,733,788 | $0.00 |
ABEJA VENTURES L L C |
14,000,000 | $0.00 |
MEHREN LAWRENCE |
14,000,000 | $1.03 |
PATIENCE JOHN |
14,000,000 | $1.03 |
SCHULER JACK W |
14,000,000 | $1.03 |
ABEJA VENTURES L L C |
14,000,000 | $1.03 |
GEIMER THOMAS V |
130,953 | $1.45 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
